RxDoctor Payments Data

Kimberly Bowen

Family · Campbellsville, KYNPI 1275100158

Payments from drug & device makers

$1,761in general payments, 2019–2025

Across 109 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Vanda Pharmaceuticals Inc.$192
  • Lilly USA, LLC$106
  • Amgen$92
  • Otsuka America Pharmaceutical, Inc.$88
  • Johnson & Johnson$85
  • plus $645 from 20 others

What the payments were for

  • Food & beverage$1,761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,761 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,796
Medicare patients
20
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab12$91,076
OzempicSemaglutide77$72,740
EliquisApixaban60$56,579
JardianceEmpagliflozin54$55,299
XareltoRivaroxaban39$44,569
LinzessLinaclotide53$41,537
FarxigaDapagliflozin Propanediol48$38,245
VraylarCariprazine Hcl25$38,098
TrulicityDulaglutide35$33,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,747
UbrelvyUbrogepant16$19,651
QuliptaAtogepant17$18,148
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen715$17,499
MounjaroTirzepatide17$16,897
JanuviaSitagliptin Phosphate29$16,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar, Ubrelvy, Qulipta$554$117,434111 claims
Novo NordiskOzempic$28$72,74077 claims
Boehringer IngelheimJardiance, Stiolto Respimat$14$63,85166 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$17$57,03985 claims
Lilly USA, LLCTrulicity, Mounjaro$106$50,05752 claims
Johnson & JohnsonXarelto$85$44,56939 claims
MerckJanuvia$37$16,41429 claims
Otsuka America Pharmaceutical, Inc.Rexulti$88$16,18011 claims
Sanofi-aventis U.S. LLCLantus$19$1,54218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Campbellsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →